CMS Issues Notice of Hydrocodone Combination Product Coverage Changes for WCMSA Proposals Submitted on or after January 1, 2015

In October 2014, the U.S. Drug Enforcement Administration rescheduled all hydrocodone combination products from schedule C-III controlled substances to C-II controlled substances. C-II controlled substances require new prescriptions at intervals no greater than 30 days, though a practitioner may issue up to three consecutive prescriptions in one visit (essentially authorizing the patient to receive a total of up to a 90 day supply of a C-II controlled substance).

As a result, the Centers for Medicare and Medicaid Services has announced that its WCMSA guidelines will change on January 1, 2015, to require a minimum of 4 healthcare provider visits per year when schedule II controlled substances (including hydrocodone combination products) are used continuously. documentation.

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram